AstraZeneca (XTER:ZEG) Net Change in Cash : €-2,219 Mil (TTM As of Mar. 2025)

View and export this data going back to 2001. Start your Free Trial

What is AstraZeneca Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

AstraZeneca's Net Change in Cash for the three months ended in Mar. 2025 was €-205 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2025 was €-2,219 Mil.

AstraZeneca Net Change in Cash Historical Data

The historical data trend for AstraZeneca's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AstraZeneca Net Change in Cash Chart

AstraZeneca Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Change in Cash

Get a 7-Day Free Trial

1,909.51

-1,334.58

-51.92

-317.28

-198.64

AstraZeneca Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Net Change in Cash	Get a 7-Day Free Trial															1,890.60	-942.94	-2,020.04	949.27	-205.35

AstraZeneca Net Change in Cash Calculation

AstraZeneca's Net Change in Cash for the fiscal year that ended in Dec. 2024 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	11327.255	+	-7620.9	+	-3816.18	+	-88.815
	=	-199

AstraZeneca's Net Change in Cash for the quarter that ended in Mar. 2025

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= 3434.525 + -1159.025 + -2503.975 + 23.125

= -205

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2,219 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AstraZeneca Net Change in Cash Related Terms
Thank you for viewing the detailed overview of AstraZeneca's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

AstraZeneca Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca PLC (XTER:ZEG) » Definitions » Net Change in Cash

Comparable Companies

LSE:GSK LLY JNJ ABBV OCSE:NOVO B XSWX:ROG XSWX:NOVN MRK AMGN PFE GILD XPAR:SAN BMY TSE:4519 TSE:4568 SHSE:600276 XTER:BAYN TSE:4578 BIIB TSE:4503

Traded in Other Exchanges

AZNCF:USA AZN:USA AZN:Sweden AZNN:Mexico AZNl:UK AZN:UK A1ZN34:Brazil AZNA:Austria AZN:Argentina

Address

1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA

Website

https://www.astrazeneca.com

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.

AstraZeneca Headlines

No Headlines